PREDICTIVE AND PROGNOSTIC SIGNIFICANCE OF PRE-TREATMENT LYMPHOCYTE COUNT IN PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA TREATED WITH PLATINUM-BASED FIRST-LINE CHEMOTHERAPY-Reference-Cited by-同舟云学术

PREDICTIVE AND PROGNOSTIC SIGNIFICANCE OF PRE-TREATMENT LYMPHOCYTE COUNT IN PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA TREATED WITH PLATINUM-BASED FIRST-LINE CHEMOTHERAPY

Published:2019-07-20 Issue:3 Volume:110 Page:160-167
ISSN:0021-5287
Container-title:The Japanese Journal of Urology
language:en
Short-container-title:Jpn. j. urol

Author:

Umemoto Susumu¹,Noguchi Go¹,Tsutsumi Sohgo¹,Kobayashi Kota¹,Ousaka Kimito¹,Kishida Takeshi¹

Affiliation:

1. Department of Urology, Kanagawa Cancer Center

Publisher

Japanese Urological Association

Subject

Urology

Link

https://www.jstage.jst.go.jp/article/jpnjurol/110/3/110_160/_pdf

Reference22 articles.

1. 1) von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM and Conte PF: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol, 18 (17), 3068-3077, 2000.

2. 2) von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A and Arning M: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol, 23 (21), 4602-4608, 2005.

3. 3) Tanji N, Ozawa A, Miura N, Yanagihara Y, Sasaki T, Nishida T, Kikugawa T, Ikeda T, Ochi T, Shimamoto K, Aoki K and Yokoyama M: Long-term results of combined chemotherapy with gemcitabine and cisplatin for metastatic urothelial carcinomas. Int J Clin Oncol, 15 (4), 369-375, 2010.

4. 4) Zou W and Chen L: Inhibitory B7-family molecules in the tumor microenvironment. Nat Rev Immunol, 8 (6), 467-477, 2008.

5. 5) Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P and CheckMate 025 Investigators: Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med, 373 (19), 1803-1813, 2015.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment;BMC Cancer;2020-09-25